US · ongoing · ~6 min read
Spradlin v. Elanco
2026–present · flea and tick medication
Elanco's flea-and-tick antitrust settlement is only preliminarily approved. The final hearing is April 1, 2027, so the case is still open.
The story
Buyers of certain imidacloprid pet products sued over exclusive dealing.
On September 17, 2026 the court preliminarily approved $9.275 million and a five-year change to the discount.
Final approval is set for April 1, 2027.
Why it matters
Pet owners are the proposed class.
A hearing date in 2027 means the deal can still change.
What was claimed
Exclusivity discounts kept generics off pet-specialty shelves.
The other side
Elanco can settle without admitting a violation. The judge can still reject the deal.
What it means for you
Do not expect a payment before the April 2027 hearing and any claims process.
Bottom line
The Elanco case stays live until the April 1, 2027 final approval hearing.
Timeline
17 September 2026
Preliminary approval
The Southern District of Indiana preliminarily approved a $9.275 million settlement and set a final hearing for April 1, 2027.
Key dates
- Preliminary approval
- 17 September 2026
- Final hearing set
- 1 April 2027
Formal snapshot
Summary: Consumers allege Elanco used exclusivity discounts to keep generic flea-and-tick products off pet-store shelves. Preliminary approval was granted September 17, 2026. The final hearing is April 1, 2027.
Regulator / plaintiff argument: The settlement, if approved, would end a challenged exclusivity discount for five years and pay the class.
Outcome: The settlement is not final. The court set the final approval hearing for April 1, 2027.
Conduct tags
Laws referenced
- Sherman Act §1 — 15 U.S.C. §1
Companies
Reader signals
0 reads · synced via local demo storage — add NEXT_PUBLIC_SUPABASE_* to enable shared likes and comments
Comments
No comments yet — start the thread.